The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.

BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.

RTW Investments has a series C for the UT Southwestern and Gladstone Institutes spinout, which will progress its lead asset into the clinic.

Point72 Ventures has led a $90m series C round for Shield AI, whose leadership includes Carnegie Mellon University’s associate research professor Nathan Michael.

University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.

The Kyoto University spinout backed by the institution’s i-Cap fund has secured $25.5m in funding from returning investors.